Company profile
Artiva Biotherapeutics, Inc.
Pipeline3 assets
- AlloNKAB-101 / AlloNK® / CD20 combinations / Allogeneic off-the-shelf non-genetically modified cryopreserved NK cell therapy / Autoimmune disease; oncologyRefractory rheumatoid arthritisPhase 2aongoing; lead indication; Fast TrackUSSjögren’s diseasePhase 2aongoingUSIdiopathic inflammatory myopathiesPhase 2aongoingUS
- CAR-NKAB-205 / CD5 / Allogeneic anti-CD5 CAR-NK cell therapy expressing soluble IL-15 / OncologyHematologic malignanciesPreclinicalcollaborator-funded
- CAR-NKAB-201 / HER2 / Allogeneic anti-HER2 CAR-NK cell therapy expressing soluble IL-15 / OncologySolid tumorsPreclinicalcollaborator-funded; US orphan drug designationUS